Rhabdomyosarcoma clinical trials

The registry lists 238 studies for Rhabdomyosarcoma across more than 10 countries. 49 are recruiting or about to start. 64 of them are mainly about Rhabdomyosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its narrower condition Rhabdomyosarcoma, Embryonal too: 243 studies, 52 open.

Get an email when these change. Save the Rhabdomyosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 119
Recruiting: 39
Active, not recruiting: 29
Terminated: 18
Status unknown: 11
Withdrawn: 10

Phase

Phase 2: 120
Phase 1: 101
Phase 3: 15
Early Phase 1: 3
Phase 4: 2

Where

United States: 179
Canada: 32
Australia: 23
France: 23
Puerto Rico: 22
Germany: 18

Who runs them

National Cancer Institute (NCI) (40) · Children's Oncology Group (19) · St. Jude Children's Research Hospital (17) · European Organisation for Research and Treatment of Cancer - EORTC (11) · Baylor College of Medicine (7) · Memorial Sloan Kettering Cancer Center (6) · Emory University (5) · Sun Yat-sen University (4)

What is being tested here

Drugs under test in Rhabdomyosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	5	5	14
Irinotecan	4	1	13
Doxorubicin	2	4	15
Liposomal doxorubicin	2	0	4
Fludarabine	2	0	4
Zoledronic Acid	2	0	2
Pegylated TOP1 Inhibitor PEEL-224	2	0	2
Ifosfamide	1	5	11
Vincristine	1	5	9
Temozolomide	1	0	9

Drug classes tested here Alkylating agents 6 open · Tyrosine kinase inhibitors (TKIs) 4 open · Antimetabolites 2 open · HDAC inhibitors 2 open · Antimitotic agents 1 open

Coming up

4phase 3 studies under way

24studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors · Valent Technologies, LLC
Dec 2026Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy · St. Jude Children's Research Hospital
Dec 2026Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas · The Hospital for Sick Children
Dec 2026Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors · University of Wisconsin, Madison
Dec 2026Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors · South Plains Oncology Consortium
Dec 2026Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma · Jonsson Comprehensive Cancer Center
Dec 2026Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors · Fudan University
Dec 2026Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma · St. Jude Children's Research Hospital
Dec 2026Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies · New York Medical College
Jan 2027VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors · University of Texas Southwestern Medical Center

Who these studies take

Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger. 35 (90%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 39
Age	Women	Men
10	33 (85%)	33 (85%)
18	39 (100%)	39 (100%)
30	20 (51%)	20 (51%)
40	14 (36%)	14 (36%)
50	11 (28%)	11 (28%)
65	9 (23%)	9 (23%)
75	9 (23%)	9 (23%)
85	8 (21%)	8 (21%)

Across all 238 studies, recruiting or not: 74% stop at 75 or younger and 70% at 65; 88% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Rhabdomyosarcoma studies take

Of 39 phase 2 interventional studies under Rhabdomyosarcoma, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	89 mo65–134 · 38 studies	—	—
Phase 1/2	62 mo48–65 · 21 studies	—	—
Phase 2	63 mo40–92 · 39 studies	—	70 mo41–94 · 36 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 238. Browse all 238 → or search them.